Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

Has known clinically active central nervous system (CNS) involvement

Has received prior therapy with an anti-lymphocyte activation gene-3 (LAG-3) antibody

Has received chimeric antigen receptors (CAR)-T-cell therapy for cHL and DLBCL Cohorts

Has received prior anticancer therapy or thoracic radiation therapy within 14 days before the first dose of study treatment

Has ≥Grade 2 non-hematological residual toxicities from prior therapy

Has had a prior anticancer monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤Grade 1 or at baseline) from AEs due to agents administered ≥4 weeks earlier

Has received a live vaccine within 30 days prior to first dose of study treatment. Administration of killed vaccines are allowed

Has received an investigational agent or used an investigational device within 4 weeks prior to intervention administration

Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug

Has a known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy

Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs)

Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis

Has an active infection requiring intravenous systemic therapy

Has a known history of human immunodeficiency virus (HIV) infection

Has known, active hepatitis B or hepatitis C infection

Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment

Has had an allogeneic hematopoetic stem cell/solid organ transplantation within the last 5 years

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

What this study is about

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

What this study is about